Girard Partners’s BioTelemetry, Inc. BEAT Stock Holding History

Girard Partners’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-250	Closed	-$16K	–	960
2018 Q3	$16K	Buy	+250	New	+$13.9K	﹤0.01%	650

Other funds holding BEAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Girard Partners's BEAT Position: Q4 2018 in Review

Girard Partners sold out of BioTelemetry, Inc. (BEAT) in Q4 2018, closing a stake of 250 shares — an estimated $16K sold.

Girard Partners first reported a position in BEAT in Q3 2018 and held it in 1 quarter. The position peaked at $16K in Q3 2018. 281 funds tracked by Wall St. Rank hold BEAT as of Q4 2018.

Girard Partners reported no remaining BioTelemetry, Inc. position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 250 BioTelemetry, Inc. shares in Q4 2018, an estimated $16K.
Girard Partners first reported a position in BioTelemetry, Inc. in Q3 2018 and held it in 1 quarter.
Girard Partners's BioTelemetry, Inc. position peaked at $16K in Q3 2018.
281 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.